Table 3 Comparison of the 74 mucormycosis according to the surgical status

Age, years, mean (SD)^a

50.6 (16.6)

49.2 (19.6)

51.5 (14.8)

0.60

Sex-ratio (H/F)

1.96

1.1

2.92

0.08

Underlying disease

 Hematological malignancies, n (%)

41 (55.4)

12 (44.4)

29 (61.7)

0.23

 Acute myeloid leukemia, n (%)

15 (20.3)

5 (18.5)

10 (21.3)

1

 Acute lymphoblastic leukemia, n (%)

10 (13.5)

3 (11.1)

7 (14.9)

0.74

 Lymphoma, n (%)

8 (10.8)

3 (11.1)

5 (10.6)

1

 Multiple myeloma, n (%)

2 (2.7)

0

2 (4.3)

0.53

 Myelodysplastic syndrome, n (%)

2 (2.7)

0

2 (4.3)

0.53

 Other, n (%)

4 (5.4)

1 (3.7)

3 (6.4)

1

 Allogenic HSCT, n (%)

16 (21.6)

3 (11.1)

13 (27.7)

0.14

 Autologous HSCT, n (%)

7 (9.5)

1 (3.7)

6 (12.8)

0.41

 Solid malignancies, n (%)

4 (5.4)

1 (3.7)

3 (6.4)

1

 SOT, n (%)

9 (12.2)

4 (14.8)

5 (10.6)

0.72

 Inflammatory disease, n (%)

2 (2.7)

1 (3.7)

1 (2.1)

1

 Systemic steroids, n (%)

30 (40.5)

8 (29.6)

22 (46.8)

0.15

 Diabetes, n (%)

11 (14.9)

1 (3.7)

10 (21.3)

0.05

Other condition, n (%)

 Chronic alcoholism, n (%)

8 (10.8)

3 (11.1)

5 (10.6)

1

 Malnutrition, n (%)

24 (32.4)

10 (37.0)

14 (29.8)

0.70

 Drug addiction, n (%)

1 (1.4)

0

1 (2.1)

1

 Chronic renal failure, n (%)

7 (9.5)

3 (11.1)

4 (8.5)

1

 Respiratory disease, n (%)

15 (20.3)

2 (7.4)

13 (27.7)

0.13

 Cirrhosis, n (%)

1 (1.4)

0

1 (2.1)

1

 Trauma, n (%)

7 (9.5)

2 (7.4)

5 (10.6)

1

 Burn, n (%)

3 (4.1)

2 (7.4)

1 (2.1)

0.55

Previous antifungal therapy, n (%)

30 (40.5)

7 (25.9)

23 (48.9)

0.09

Site of infection

 Lungs, n (%)

29 (39.2)

5 (18.5)

24 (51.1)

0.01

 Skin, n (%)

15 (20.3)

8 (29.6)

7 (14.9)

0.22

 Sinus and ENT infection, n (%)

1 (1.35)

1 (1.4)

0

0.36

 Abdomen, n (%)

1 (1.35)

1 (1.4)

0

0.36

 Bones, n (%)

1 (1.35)

0

1 (2.1)

1

 Infection of contiguous sites, n (%)

13 (17.6)

7 (25.9)

6 (12.8)

0.26

 Disseminated infection, n (%)

14 (18.9)

4 (14.8)

10 (21.3)

0.55

Isolated fungi

0.02

 Rhizopus genus, n (%)

22 (29.7)

7 (25.9)

15 (31.9)

 Mucor genus, n (%)

10 (13.5)

2 (7.4)

8 (17.0)

 Rhizomucor genus, n (%)

14 (18.9)

4 (14.8)

10 (21.3)

 Lichtheimia genus, n (%)

19 (25.7)

7 (25.9)

12 (25.5)

 Cunninghamella genus, n (%)

1 (1.4)

0

1 (2.1)

 Unclassified mucorales, n (%)

9 (12.2)

8 (29.6)

1 (2.1)

Year of admission

0.53

Severity of infection

 SAPS2, mean (SD)^a

52 (22)

44.6 (17.5)

56.6 (22.5)

0.01

 SOFA, mean (SD)^a

9 (4)

7.0 (3.3)

9.9 (3.7)

0.001

 Respiratory

2.0 (1.2)

1.5 (1.3)

2.2 (1.1)

0.01

 Cardiovascular

1.7 (1.8)

1.4 (1.6)

1.9 (1.8)

0.18

 Renal

1.1 (1.2)

1.2 (1.2)

1.1 (1.2)

0.63

 Hematological

2.0 (1.4)

1.4 (1.2)

2.3 (1.5)

0.006

 Neurological

1.2 (1.5)

0.8 (1.3)

1.4 (1.6)

0.08

 Liver

0.8 (0.9)

0.6 (0.8)

0.9 (0.9)

0.17

Biological abnormalities

 TP < 50%, n (%)

13 (17.6)

2 (7.41)

11 (23.4)

0.12

 Thrombocytes < 50G/L, n (%)

27 (36.5)

5 (18.5)

22 (46.8)

0.02

 Leucocytes < 1G/L, n (%)

23 (31.1)

6 (22.2)

17 (36.2)

0.32

 Interventions

 Vasopressors

53 (71.6)

18 (66.7)

35 (74.5)

0.65

 Mechanical ventilation

66 (89.2)

21 (77.8)

45 (95.7)

0.05

 Renal replacement therapy

31 (41.9)

14 (51.9)

17 (36.2)

0.23

 Delay of efficient antifungal treatment, mean (SD)^a

9.5 (9.9)

10.2 (8.7)

8.9 (11.2)

0.64